CAR T cells produced in vivo to treat cardiac injury

Fibrosis affects millions of people with cardiac disease. We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) in T cell–targeted lipid nanoparticles (LNPs). The efficacy of these in vivo–re...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science (American Association for the Advancement of Science) 2022-01, Vol.375 (6576), p.91-96
Hauptverfasser:	Rurik, Joel G, Tombácz, István, Yadegari, Amir, Méndez Fernández, Pedro O, Shewale, Swapnil V, Li, Li, Kimura, Toru, Soliman, Ousamah Younoss, Papp, Tyler E, Tam, Ying K, Mui, Barbara L, Albelda, Steven M, Puré, Ellen, June, Carl H, Aghajanian, Haig, Weissman, Drew, Parhiz, Hamideh, Epstein, Jonathan A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adoptive Transfer Animals Antigens Cardiac function Cardiovascular diseases CD5 antigen CD5 Antigens - immunology Cell Engineering Chimeric antigen receptors Congestive heart failure Coronary artery disease Endopeptidases - immunology Endopeptidases - metabolism Fibroblasts - immunology Fibroblasts - pathology Fibrosis Fibrosis - therapy Heart Heart diseases Heart Diseases - pathology Heart Diseases - therapy Heart Disorders Heart Failure - therapy HEK293 Cells Humans Immunotherapy Immunotherapy, Adoptive Injury prevention Lipids Liposomes Lymphocytes Lymphocytes T Male Membrane Proteins - immunology Membrane Proteins - metabolism Mice Mice, Inbred C57BL Motor Vehicles mRNA Myocardium - pathology Nanoparticles Plasma membranes Receptors Receptors, Chimeric Antigen - genetics Receptors, Chimeric Antigen - immunology Receptors, Chimeric Antigen - metabolism RNA, Messenger - genetics Scars Spleen Spleen - immunology Stiffening T-Lymphocytes - immunology Therapeutic applications Trogocytosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!